Where federal marijuana rescheduling actually stands in May 2026

For nearly two years, "federal rescheduling" sat in a holding pattern. The Department of Health and Human Services recommended it in 2023. The Drug Enforcement Administration issued a proposed rule in May 2024. An administrative-law-judge (ALJ) hearing was scheduled in late 2024 and then stayed in January 2025. The presiding ALJ retired in August 2025 with the docket still open. As of the start of 2026, the proposed rule was technically alive but functionally frozen.

That changed on April 22, 2026, when Acting Attorney General Todd Blanche signed a final order moving two narrow categories of marijuana from Schedule I to Schedule III, effective immediately. The DOJ simultaneously announced an expedited ALJ hearing starting June 29, 2026 to consider whether the rest of the cannabis category should follow. Both actions were published in the Federal Register on April 28, 2026.

This article maps what the April order did, what it did not do, and what is realistically at stake in June.

What the April 22 order moved to Schedule III

The DOJ final order covers exactly two categories of marijuana:

1. FDA-approved drug products containing marijuana. As of May 2026 this means Epidiolex (cannabidiol oral solution for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex). It is the only FDA-approved marijuana-derived drug on the market.
2. Marijuana subject to a state-issued license to manufacture, distribute, or dispense for medical purposes only. This captures licensed medical-cannabis operators in the roughly 38 states with regulated medical programs.

Everything else (unlicensed adult-use product, bulk marijuana not yet incorporated into an approved drug, synthetic THC, and the underlying plant material outside a state medical license) remains Schedule I. The Federal Register's accompanying withdrawal notice formally pulled the original May 2024 proposed rule that would have rescheduled all marijuana, replacing it with this narrower final order plus the June hearing process.

The mechanism the DOJ used was a direct rulemaking final order rather than the conclusion of the prior notice-and-comment process. This is a structurally unusual approach and one of the targets of the constitutional challenges discussed below.

What changes for state medical-cannabis operators

For a state-licensed medical-cannabis dispensary, cultivator, or processor, the Schedule III move has three concrete effects:

• Section 280E. The federal tax-code provision that disallows ordinary business deductions for sellers of Schedule I and II controlled substances no longer applies. State medical operators may deduct rent, payroll, utilities, and other ordinary expenses on federal returns going forward. This is the single largest financial change for the industry from rescheduling.
• DEA registration pathway. Schedule III substances can be lawfully prescribed by DEA-registered practitioners and dispensed through DEA-registered facilities. The DOJ has signaled an expedited DEA registration mechanism for state-licensed operators, though the operational details remain to be promulgated.
• Research access. Schedule III status meaningfully lowers the procedural barrier to FDA- and NIH-funded cannabis research using state-licensed product.

What does not change automatically for these operators:

• State-level licensing, regulation, and taxation remain governed entirely by state law.
• Federal banking access still depends on the SAFE Banking Act (or its successor) clearing Congress, which it has not.
• Interstate commerce in cannabis remains federally prohibited; state medical-license status does not authorize crossing state lines.
• The FDA's authority over drug approval is unaffected. Schedule III status does not make any cannabis product an "approved drug."

What does not change for patients

For the patient holding a state medical-cannabis card, the day-to-day experience is essentially identical to what it was on April 21, 2026. The medical card is issued by the state, qualifying conditions are defined by state statute, dispensary inventory is regulated by the state, and the patient's transaction occurs within a single-state regulatory perimeter.

What rescheduling does not do for patients:

• It does not authorize physicians to "prescribe" cannabis the way they prescribe Schedule III drugs like ketamine or testosterone. Cannabis sold through state programs is still certified or recommended under state law, not prescribed under federal law.
• It does not create insurance coverage. Medical cannabis remains out-of-pocket nationally because (1) it lacks FDA approval as a drug for any specific indication outside Epidiolex's narrow labeling, and (2) Medicare, Medicaid, and most private insurers tie coverage to FDA-approved indications.
• It does not change federal employment, security-clearance, or DOT-regulated transportation rules for cannabis users. (See the companion article on federal employment for the operational details.)

The June 29 ALJ hearing

The expedited ALJ hearing begins June 29, 2026, at 9:00 a.m. ET at the DEA Hearing Facility (700 Army Navy Drive, Arlington, VA) and is scheduled to conclude no later than July 15, 2026. The ALJ has not yet been formally designated by the Attorney General. The hearing's stated purpose: receive evidence on whether all forms of marijuana should be downscheduled from Schedule I to Schedule III through the formal rulemaking process.

The procedural posture is unusual. The Federal Register withdrawal notice characterized the prior 2024 rulemaking as a "previously initiated proceeding" that the DOJ is now replacing with this hearing. Several interested parties (state medical-cannabis trade associations, patient-advocacy organizations, and at least one cannabis-industry coalition) have filed motions to intervene. As of mid-May 2026 the ALJ panel composition, the formal participant list, and the evidentiary schedule remain in flux.

The political reading: the April 22 order is a partial concession (move the medical and FDA categories now, capture the political win, defer the harder question of full rescheduling to the hearing). The June hearing is the formal proceeding through which broader rescheduling could occur, and it is also the proceeding most likely to produce a litigated record that the next administration can either ratify or unwind.

The constitutional question hanging over both proceedings

The Department of Justice has formally admitted in federal court that the DEA's administrative-law-judge structure (specifically, the dual-layer for-cause removal protection for DEA ALJs) violates the United States Constitution under the Supreme Court's reasoning in Free Enterprise Fund v. PCAOB (2010) and subsequent cases. The same DOJ that owns the rescheduling proceedings is on record characterizing the adjudicative officers running them as constitutionally infirm.

This creates a structural risk: any final rulemaking output of the June 29 hearing is vulnerable to a constitutional challenge that the agency itself acknowledges. Practitioners watching the proceeding expect at least one such challenge to be filed within weeks of any final order. Whether the courts ultimately treat the constitutional defect as fatal or curable is genuinely uncertain. There is no Supreme Court precedent directly on point for an ALJ proceeding the executive branch has already admitted is unconstitutionally structured.

What rescheduling has never been able to do

A piece of conventional wisdom worth dismantling: rescheduling to Schedule III is not legalization, is not decriminalization, and is not federal preemption of state cannabis policy. It is a technical reclassification within the Controlled Substances Act that changes the federal tax treatment of state-licensed sellers, lowers the research-access barrier, and (in this narrower form) signals that the executive branch no longer treats FDA-approved and state-medical cannabis as "no currently accepted medical use" substances.

It does not:

• Authorize interstate commerce in cannabis.
• Make adult-use cannabis legal in any state where it is not already legal under state law.
• Resolve the conflict between federal Schedule I status (for everything outside the April 22 order) and state legalization regimes.
• Provide patient employment protections, parental-rights protections, or housing protections at the federal level.

For Congress to address those questions requires legislation. The most-discussed vehicles (SAFE Banking, the STATES 2.0 Act, the various Cannabis Administration and Opportunity Act drafts) have not advanced through the 119th Congress to date.

How the April 22 order interacts with state medical-cannabis statutes

A practical question that has dominated state-regulator listservs since the April 22 order: does the rescheduling preempt or modify state medical-cannabis statutes? The answer is no on both counts.

The DOJ final order is structured as a federal scheduling change, not as a federal medical-cannabis program. It does not:

• Create a federal qualifying-condition list that state programs must adopt.
• Establish federal patient-registry requirements that state programs must implement.
• Set federal possession or product-form rules that override state rules.
• Authorize DEA-registered practitioners to "prescribe" cannabis through state programs (state programs continue to operate through certification and recommendation mechanisms distinct from controlled-substance prescribing).
• Preempt state employment-protection, housing, or family-law statutes that vary widely between medical-cannabis states.

What it does do is recognize state medical-cannabis license status as a federal-controlled-substance category. The practical effect is to remove the inherent contradiction between (a) state programs that issue licenses to manufacture and dispense a federally Schedule I substance, and (b) federal law that has historically treated those state-licensed activities as ongoing federal violations subject to prosecutorial discretion. After April 22, 2026, state-licensed activities are federally Schedule III activities. The discretion question is partially resolved; the structural questions about banking, taxation, and operator-level regulatory compliance flow from there.

For patients and operators in non-medical-only legalization states (Colorado, Washington, Michigan, Massachusetts, California, Illinois, New York, others where adult-use is also legal), the April 22 order has more limited direct effect. State adult-use programs are explicitly excluded from the order's coverage. The same operators may hold both medical and adult-use licenses; the medical license now produces Schedule III status for the medical product line, while the adult-use license continues to produce Schedule I status for the adult-use product line. Operators with both license types are managing two parallel federal-tax and federal-registration postures within a single business.

What this means for cannabis-derived pharmaceutical development

One of the under-discussed implications of the April 22 order is its effect on the FDA-approved cannabis-derived drug development pipeline. As of May 2026, exactly one FDA-approved cannabis-derived drug is on market: Epidiolex (cannabidiol oral solution) for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Several additional cannabinoid products have been in clinical development for indications including chemotherapy-induced nausea, multiple sclerosis spasticity, pediatric epilepsy syndromes outside Epidiolex's indications, and chronic pain.

The Schedule I status of cannabis through 2025 was a real procedural barrier to this pipeline. DEA-registered research access, clinical-trial cannabis product sourcing, and the procedural friction of working with a Schedule I substance combined to slow FDA-track cannabis drug development relative to other therapeutic categories. The Schedule III move materially lowers each of those friction points.

What that translates to in actual approvals depends on factors beyond rescheduling: the underlying clinical-evidence base for specific indications, the regulatory posture of FDA's Center for Drug Evaluation and Research, and the willingness of pharmaceutical sponsors to invest in cannabis-derived drug development. Industry observers expect a modest acceleration of pipeline submissions through 2027–2028, but this is not the wave of new approvals some headline coverage has suggested. Drug development cycles run in years, not months.

What to watch through the rest of 2026

Three milestones will determine whether the April 22 order becomes a stable new equilibrium or an interim step:

1. The June 29–July 15 hearing record. If the ALJ produces findings supporting broader rescheduling, the DOJ has political and procedural room to issue a second final order. If the record is contested, expect litigation before any further order issues.
2. The first constitutional challenge filing. A motion attacking the ALJ structure under the DOJ's own admission would test whether the rescheduling produced to date survives.
3. DEA registration rulemaking for state medical operators. The April 22 order names an expedited pathway but does not establish the operational rules. The DEA's implementation document, once it issues, will determine how quickly state medical operators can actually exercise Schedule III status.

For now, the most accurate summary of federal rescheduling in May 2026 is: it has happened for two specific categories, it has not happened for everything else, and the question of whether the rest follows is the substance of a hearing that begins in five weeks.

[Last reviewed 2026-05-18. This is informational only — not medical or legal advice.]